4 news items
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
TPST
18 Jun 24
mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TPST
7 Jun 24
investigation in a randomized global study in first-line cancer patients. Tempest is headquartered in Brisbane, California. More information about Tempest
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
TPST
31 May 24
Glancy Prongay & Murray LLP ("GPM") announces its investigation of Tempest Therapeutics, Inc
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
TPST
9 May 24
novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest
- Prev
- 1
- Next